Recent News

• 03.19.2026 - MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
• 03.06.2026 - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.03.2026 - Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
• 02.24.2026 - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
• 02.06.2026 - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 01.09.2026 - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 02.24.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.24.2026 - EX-99.1 EX-99.1
• 02.24.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 02.24.2026 - 8-K Current report
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 4/A Statement of changes in beneficial ownership of securities